Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma-Reference-Cited by-同舟云学术

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Published:2017-05-04 Issue:18 Volume:129 Page:2471-2478
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Herbaux Charles¹,Gauthier Jordan¹,Brice Pauline²,Drumez Elodie³,Ysebaert Loic⁴,Doyen Hélène⁵,Fornecker Luc⁶,Bouabdallah Krimo⁷,Manson Guillaume⁸,Ghesquières Hervé⁹,Tabrizi Reza¹⁰,Hermet Eric¹¹,Lazarovici Julien¹²,Thiebaut-Bertrand Anne¹³,Chauchet Adrien¹⁴,Demarquette Hélène¹,Boyle Eileen¹,Houot Roch⁸,Yakoub-Agha Ibrahim¹¹⁵,Morschhauser Franck¹¹⁶

Affiliation:

1. Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille, France;

2. Service d’Onco-hématologie, CHU Paris Saint-Louis, Lariboisière, Paris, France;

3. Université Lille Nord de France, Equipe Biostatistique, Lille, France;

4. Département d’Hématologie Oncopole, Toulouse, France;

5. Service d’Onco-hématologie, CHU de Tours, Tours, France;

6. Service d’Onco-hématologie, CHU de Strasbourg, Strasbourg, France;

7. Service des Maladies du Sang, Hôpital Haut-Lévèque, Pessac, France;

8. Department of Hematology, CHU Rennes, Rennes, France;

9. Service d’Onco-hématologie, Unicancer, Lyon, France;

10. Service d’Onco-hématologie, CHU de Bordeaux, Bordeaux, France;

11. Service d’Onco-hématologie, CHU de Clermont-Ferrand, Clermont-Ferrand, France;

12. Service des Maladies du Sang, Institut Gustave Roussy, Villejuif, France;

13. Service des Maladies du Sang, CHU de Grenoble, Grenoble, France;

14. Service d’Onco-hématologie, CHU de Besançon, Besançon, France;

15. Lille Inflammation Research International Center INSERM U995, Lille, France; and

16. Université de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, France

Abstract

Key Points PD-1 blockade with nivolumab provides durable disease control after allo-HCT. PD-1 blockade with nivolumab after allo-HCT is associated with 30% acute GVHD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/18/2471/1399972/blood749556.pdf

Reference26 articles.

1. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation;Sureda;Haematologica,2012

2. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors;Kanate;Blood,2016

3. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis;Rashidi;Bone Marrow Transplant,2016

4. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma;Burroughs;Biol Blood Marrow Transplant,2008

5. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma;Raiola;Bone Marrow Transplant,2014

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice;Cancers;2024-05-10

2. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan;International Journal of Hematology;2024-03-23

3. Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD;Blood;2024-01-11

4. Classical Hodgkin’s Lymphoma;The EBMT Handbook;2024

5. Mechanisms of Immune Resistance;The EBMT Handbook;2024